Report period | 2019 | 2020 | 2021 | 2022 | 2023 | Q2 24 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
ARCT:US | Arcturus Therapeutics Holdings | Common share | - | US03969T1097 | $16.94 |
Company name | Arcturus Therapeutics Holdings |
---|---|
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
Business address | 10628 Science Center Drive San Diego, CA 92121 United States |
Mailing address | 10628 Science Center Drive San Diego, CA 92121 United States |
Website | ir.arcturusrx.com |
Information disclosure | www.sec.gov |